Richard L Momparler

List of Publications by Citations

101 papers	4,342 citations	37 h-index	63 g-index
103 ext. papers	4,580 ext. citations	3.9 avg, IF	5.59 L-index

#	Paper	IF	Citations
101	DNA methylation and cancer. *Journal of Cellular Physiology*, **2000**, 183, 145-54	7	315
100	Cancer epigenetics. *Oncogene*, **2003**, 22, 6479-83	9.2	236
99	Pilot phase I-II study on 5-aza-2Ŧdeoxycytidine (Decitabine) in patients with metastatic lung cancer. *Anti-Cancer Drugs*, **1997**, 8, 358-68	2.4	173
98	Phase I study on 5-aza-2Ŧdeoxycytidine in children with acute leukemia. *Leukemia Research*, **1981**, 5, 453-62	2.7	166
97	Kinetic studies on 2Ţ2Ŧdifluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. *Biochemical Pharmacology*, **1993**, 45, 1857-61	6	157
96	Pharmacology of 5-Aza-2Ŧdeoxycytidine (decitabine). *Seminars in Hematology*, **2005**, 42, S9-16	4	155
95	Pharmacokinetic and pharmacodynamic analysis of 5-aza-2Ŧdeoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. *Clinical Epigenetics*, **2013**, 5, 3	7.7	143
94	Epigenetic therapy of cancer with 5-aza-2Ŧdeoxycytidine (decitabine). *Seminars in Oncology*, **2005**, 32, 443-51	5.5	129
93	Clinical trial on 5-aza-2Ŧdeoxycytidine in patients with acute leukemia **1985**, 30, 277-86		129
92	Antineoplastic action of 5-aza-2Ŧdeoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. *Cancer Chemotherapy and Pharmacology*, **2001**, 48, 71-6	3.5	104
91	Effect of cytosine arabinoside 5Ŧtriphosphate on mammalian DNA polymerase. *Biochemical and Biophysical Research Communications*, **1969**, 34, 464-71	3.4	98
90	Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2Ŧdeoxycytidine by human cytidine deaminase. *Cancer Chemotherapy and Pharmacology*, **1992**, 30, 7-11	3.5	95
89	Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2Ŧdeoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. *Leukemia Research*, **2003**, 27, 437-44	2.7	91
88	Drug resistance to 5-aza-2Ŧdeoxycytidine, 2Ţ2Ŧdifluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. *Cancer Chemotherapy and Pharmacology*, **1998**, 42, 373-8	3.5	87
87	Kinetics of deamination of 5-aza-2Ŧdeoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. *Biochemical Pharmacology*, **1983**, 32, 1327-8	6	84
86	Potential of 5-aza-2Ŧdeoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. *Lung Cancer*, **2001**, 34 Suppl 4, S111-5	5.9	83
85	Demethylation by 5-aza-2Ŧdeoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. *Anti-Cancer Drugs*, **1998**, 9, 743-50	2.4	82

84	Molecular, cellular and animal pharmacology of 5-aza-2Ŧdeoxycytidine **1985**, 30, 287-99		81
83	Comparison of the antileukemic activity of 5-AZA-2Ŧdeoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. *Leukemia Research*, **1984**, 8, 1043-9	2.7	80
82	Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2Ŧdeoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. *International Journal of Cancer* , **2003**, 103, 177-84	7.5	77
81	Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2Ŧdeoxycytidine. *Leukemia Research*, **1985**, 9, 1361-6	2.7	66
80	DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2Ŧdeoxycytidine. *Anti-Cancer Drugs*, **1999**, 10, 471-6	2.4	59
79	Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside. *Nucleic Acids and Protein Synthesis*, **1968**, 161, 481-93		59
78	5-aza-2Ŧdeoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. *Leukemia Research*, **1984**, 8, 181-5	2.7	58
77	Antineoplastic action of 5-aza-2Ŧdeoxycytidine and phenylbutyrate on human lung carcinoma cells. *Anti-Cancer Drugs*, **2002**, 13, 869-74	2.4	55
76	Epigenetic therapy of acute myeloid leukemia using 5-aza-2Ŧdeoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation. *Clinical Epigenetics*, **2014**, 6, 19	7.7	53
75	In vitro systems for evaluation of combination chemotherapy **1980**, 8, 21-35		53
74	Enhancement of antineoplastic action of 5-aza-2Ŧdeoxycytidine by zebularine on L1210 leukemia. *Anti-Cancer Drugs*, **2005**, 16, 301-8	2.4	52
73	Importance of dose-schedule of 5-aza-2Ŧdeoxycytidine for epigenetic therapy of cancer. *BMC Cancer*, **2008**, 8, 128	4.8	51
72	Activation of the retinoic acid receptor beta gene by 5-aza-2Ŧdeoxycytidine in human DLD-1 colon carcinoma cells. *Anti-Cancer Drugs*, **1997**, 8, 56-61	2.4	49
71	Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2Ŧdeoxycytidine. *Cancer Chemotherapy and Pharmacology*, **2009**, 63, 411-6	3.5	46
70	Antileukemic activity of genistein, a major isoflavone present in soy products. *Journal of Natural Products*, **2008**, 71, 3-7	4.9	44
69	Partial Purification and Properties of Two Forms of Deoxyribonucleic Acid Polymerase from Calf Thymus. *Journal of Biological Chemistry*, **1973**, 248, 285-293	5.4	44
68	Cell cycle effects and cellular pharmacology of 5-aza-2Ŧdeoxycytidine. *Cancer Chemotherapy and Pharmacology*, **1984**, 13, 191-4	3.5	43
67	Comparison of the induction of apoptosis in human leukemic cell lines by 2Ţ2Ŧdifluorodeoxycytidine (gemcitabine) and cytosine arabinoside. *Leukemia Research*, **1995**, 19, 849-56	2.7	42

66	Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2Ŧdeoxycytidine (decitabine) on human breast carcinoma cells. *Cancer Chemotherapy and Pharmacology*, **2006**, 58, 618-25	3.5	40
65	Preclinical evaluation of the antineoplastic action of 5-aza-2Ŧdeoxycytidine and different histone deacetylase inhibitors on human Ewingŧs sarcoma cells. *Cancer Cell International*, **2008**, 8, 16	6.4	37
64	Interaction of 5-aza-2Ŧdeoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. *Anti-Cancer Drugs*, **2003**, 14, 193-202	2.4	36
63	Mammalian Deoxynucleoside Kinases. *Journal of Biological Chemistry*, **1971**, 246, 2745-2751	5.4	34
62	Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation. *Leukemia Research*, **2012**, 36, 1049-54	2.7	33
61	Evaluation of antineoplastic action of 5-aza-2Ŧdeoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines. *Anti-Cancer Drugs*, **2004**, 15, 161-7	2.4	33
60	Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia. *Experimental Hematology and Oncology*, **2013**, 2, 20	7.8	32
59	Targeting of cancer stem cells by inhibitors of DNA and histone methylation. *Expert Opinion on Investigational Drugs*, **2015**, 24, 1031-43	5.9	31
58	Comparison of antineoplastic activity of 2Ţ2Ŧdifluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells. *Anti-Cancer Drugs*, **1991**, 2, 49-55	2.4	30
57	Interaction of retinoic acid and vitamin D3 analogs on HL-60 myeloid leukemic cells. *Leukemia Research*, **1993**, 17, 749-57	2.7	29
56	Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene. *Cancer Gene Therapy*, **2001**, 8, 669-76	5.4	27
55	Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2Ŧdeoxycytidine. *Leukemia Research*, **1990**, 14, 751-4	2.7	27
54	Mammalian Deoxynucleoside Kinases. *Journal of Biological Chemistry*, **1971**, 246, 6152-6158	5.4	25
53	Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2Ŧdeoxycytidine). *Frontiers in Oncology*, **2013**, 3, 188	5.3	23
52	Cytotoxic activity of 2Ţ2Ŧdifluorodeoxycytidine, 5-aza-2Ŧdeoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene. *Biochemical and Biophysical Research Communications*, **2002**, 293, 1478-84	3.4	23
51	Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside. *Anti-Cancer Drugs*, **1996**, 7, 266-74	2.4	23
50	Evaluation of an inhibitor of DNA methylation, 5-aza-2Ŧdeoxycytidine, for the treatment of lung cancer and the future role of gene therapy. *Advances in Experimental Medicine and Biology*, **2000**, 465, 433-46	3.6	22
49	Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2Ŧdeoxycytidine and 3-deazauridine. *Cancer Chemotherapy and Pharmacology*, **1989**, 25, 51-4	3.5	22

48	Biochemical pharmacology of cytosine arabinoside. *Medical and Pediatric Oncology*, **1982**, 10 Suppl 1, 45-8		22
47	Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2Ŧdeoxycytidine against human leukemic cells of different phenotype. *Leukemia Research*, **1990**, 14, 755-60	2.7	21
46	Synergistic effect of 5-Aza-2Ŧdeoxycytidine and genistein in combination against leukemia. *Oncology Research*, **2008**, 17, 223-30	4.8	20
45	Coexpression of cytidine deaminase and mutant dihydrofolate reductase by a bicistronic retroviral vector confers resistance to cytosine arabinoside and methotrexate. *Human Gene Therapy*, **1998**, 9, 2537-44	4.8	20
44	Activation of expression of p15, p73 and E-cadherin in leukemic cells by different concentrations of 5-aza-2Ŧdeoxycytidine (Decitabine). *Anticancer Research*, **2004**, 24, 75-8	2.3	20
43	Epigenetic action of decitabine (5-aza-2Ŧdeoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C). *Leukemia Research*, **2013**, 37, 980-4	2.7	19
42	Effect of tRNA from 5-azacytidine-treated hamster fibrosarcoma cells on protein synthesis in vitro in a cell-free system. *Biochemical Pharmacology*, **1976**, 25, 389-92	6	19
41	Mammalian Deoxynucleoside Kinases. *Journal of Biological Chemistry*, **1971**, 246, 2752-2757	5.4	19
40	Mutation in the ligand-binding domain of the retinoic acid receptor alpha in HL-60 leukemic cells resistant to retinoic acid and with increased sensitivity to vitamin D3 analogs. *Leukemia Research*, **1996**, 20, 761-9	2.7	18
39	Inhibition of DNA and Histone Methylation by 5-Aza-2ŦDeoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells. *Frontiers in Oncology*, **2017**, 7, 19	5.3	17
38	Enhancement of antineoplastic action of 5-aza-2Ŧdeoxycytidine by phenylbutyrate on L1210 leukemic cells. *Leukemia and Lymphoma*, **2004**, 45, 147-54	1.9	17
37	Antineoplastic action of 5-aza-2Ŧdeoxycytidine (Dacogen) and depsipeptide on Raji lymphoma cells. *Oncology Reports*, **2004**, 11, 1253-6	3.5	17
36	3-Deazauridine enhances the antileukemic action of 5-aza-2Ŧdeoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase. *Leukemia Research*, **2011**, 35, 110-8	2.7	16
35	5-Aza-2Ŧdeoxycytidine as inducer of differentiation and growth inhibition in mouse neuroblastoma cells. *Cell Differentiation and Development*, **1989**, 27, 47-55		15
34	Coexpression of rat glutathione S-transferase A3 and human cytidine deaminase by a bicistronic retroviral vector confers in vitro resistance to nitrogen mustards and cytosine arabinoside in murine fibroblasts. *Cancer Gene Therapy*, **2000**, 7, 757-65	5.4	14
33	Enhancement of the antileukemic activity of 5-aza-2Ŧdeoxycytidine by cyclopentenyl cytosine in HL-60 leukemic cells. *Anti-Cancer Drugs*, **1994**, 5, 223-8	2.4	13
32	Effects of 5-aza-2Ŧdeoxycytidine on survival and cell cycle progression of L1210 leukemia cells. *Leukemia Research*, **1986**, 10, 533-7	2.7	13
31	Effect of 5-aza-2Ŧdeoxycytidine and vitamin D3 analogs on growth and differentiation of human myeloid leukemic cells. *Cancer Chemotherapy and Pharmacology*, **1998**, 41, 275-80	3.5	12

30	Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2Ŧdeoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells. *Anti-Cancer Drugs*, **1993**, 4, 327-33	2.4	12
29	Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells. *Cancer Chemotherapy and Pharmacology*, **1990**, 27, 141-6	3.5	10
28	Sample preparation for the determination of 5-aza-2Ŧdeoxycytidine in plasma by high-performance liquid chromatography. *Biomedical Applications*, **1985**, 345, 162-7		10
27	Enzymatic synthesis of 5-azacytidine 5Ŧtriphosphate from 5-azacytidine. *Analytical Biochemistry*, **1976**, 71, 60-7	3.1	10
26	Studies on analogs of isosteric and allosteric ligands of deoxycytidylate aminohydrolase. *Biochemistry*, **1970**, 9, 2539-43	3.2	10
25	Enhancement of anti-neoplastic activity of cytosine arabinoside against human HL-60 myeloid leukemic cells by 3-deazauridine. *International Journal of Cancer*, **1991**, 49, 573-6	7.5	9
24	Preclinical evaluation of hematopoietic toxicity of antileukemic agent, 5-aza-2Ŧdeoxycytidine. *Toxicology*, **1989**, 57, 329-36	4.4	9
23	Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2Ŧdeoxycytidine and beta-2Ŧdeoxythioguanosine. *International Journal of Cancer*, **1982**, 30, 361-64	7.5	9
22	The regulatory properties of deoxyadenosine kinase. *Nucleic Acids and Protein Synthesis*, **1968**, 161, 578-80		9
21	A Perspective on the Comparative Antileukemic Activity of 5-Aza-2Ŧdeoxycytidine (Decitabine) and 5-Azacytidine (Vidaza). *Pharmaceuticals*, **2012**, 5, 875-81	5.2	8
20	Effect of DNA polymerase on nuclei from different phases of cell cycle. *FEBS Journal*, **1974**, 49, 565-71		8
19	Kinetic studies with 5-azacytidine-5Ŧtriphosphate and DNA-dependent RNA polymerase. *Biochemical Pharmacology*, **1977**, 26, 403-6	6	7
18	Sample preparation and estimation of plasma concentration of 3-deazauridine by high-performance liquid chromatography. *Therapeutic Drug Monitoring*, **1983**, 5, 491-6	3.2	6
17	PHARMACOLOGY OF 5-AZA-2?-DEOXYCYTIDINE **1979**, 33-41		6
16	Quantitation of inhibition of DNA methylation of the retinoic acid receptor beta gene by 5-Aza-2Ŧdeoxycytidine in tumor cells using a single-nucleotide primer extension assay. *Analytical Biochemistry*, **2000**, 281, 55-61	3.1	5
15	Potential of ribozymes against deoxycytidine kinase to confer drug resistance to cytosine nucleoside analogs. *Biochemical and Biophysical Research Communications*, **2000**, 278, 569-75	3.4	5
14	Effects of trimethoprim on leukaemic cells in vitro. *British Journal of Haematology*, **1981**, 47, 221-6	4.5	5
13	Inhibition of uridine-cytidine kinase by 5-azacytidine 5Ŧtriphosphate. *Medical and Pediatric Oncology* , **1976**, 2, 265-70		4

12	Abstract 4344: Membrane-type 1 matrix metalloproteinase-mediated pro-invasive properties of neuroblastoma initiating cells **2011**,		4
11	Gene amplification of human cytidine deaminase proviral cDNA and increased levels of its mRNA produces enhanced drug resistance to cytosine arabinoside in retroviral-transduced murine fibroblasts. *Cancer Letters*, **1999**, 135, 29-36	9.9	3
10	Action of troxacitabine on cells transduced with human cytidine deaminase cDNA. *Cancer Investigation*, **2004**, 22, 25-9	2.1	3
9	Effects of 5-aza-2Ŧdeoxycytidine and interferon-alpha on differentiation and oncogene expression in HL-60 myeloid leukemic cells. *Anti-Cancer Drugs*, **1992**, 3, 281-7	2.4	3
8	Epigenetic Modulation of Self-Renewal Capacity of Leukemic Stem Cells and Implications for Chemotherapy.. *Epigenomes*, **2020**, 4,	2.3	2
7	Coexpression of Cytidine Deaminase and Mutant Dihydrofolate Reductase by a Bicistronic Retroviral Vector Confers Resistance to Cytosine Arabinoside and Methotrexate. *Human Gene Therapy*, **1998**, 9, 2537-2544	4.8	2
6	Phase I and II studies of the decitabine□genistein drug combination in advanced solid tumors.. *Journal of Clinical Oncology*, **2015**, 33, e13556-e13556	2.2	2
5	Preclinical and Clinical Studies on 5-Aza-2?-Deoxycytidine, a Potent Inhibitor of DNA Methylation, in Cancer Therapy **2005**, 205-217		1
4	Integration of biochemical, cellular, and animal pharmacology of antineoplastic agents to design new model drug combinations for treatment of acute leukemia. *Leukemia Research*, **1977**, 1, 315-322	2.7	1
3	Enhancement of the Antileukemic Action of the Inhibitors of DNA and Histone Methylation: 5-Aza-2ŦDeoxycytidine and 3-Deazaneplanocin-A by Vitamin C.. *Epigenomes*, **2021**, 5,	2.3	1
2	Relationship of nutritional factors to in vitro tumor cell growth and cytotoxicity produced by cytosine arabinoside. *Cell Proliferation*, **1977**, 10, 127-35	7.9	
1	Pharmacodynamic Responses to DNA Methyltransferase Inhibition **2014**, 171-188		